Breaking News
March 19, 2019 - Use of synthetic psychedelic linked to improvements in depression and anxiety
March 19, 2019 - Knee Pain Not Tied to Activity Levels in Knee Osteoarthritis
March 19, 2019 - Study shows benefits of delayed cord clamping in healthy babies
March 19, 2019 - A cell’s “self-destruct” function could yield new therapies
March 19, 2019 - Latest advances and perspectives of all AI types used in pharmaceutical R&D
March 19, 2019 - Prophylactic cranial irradiation used as standard approach for patients with NSCLC
March 19, 2019 - Sugar-sweetened beverages may be linked with increased risk of cardiovascular mortality
March 19, 2019 - AHA News: Black Woman in Their 50s Face Especially High Stroke Risk
March 19, 2019 - Secrets of early life revealed from less than half a teaspoon of blood
March 19, 2019 - Immune cells engineered to tattle on suspicious cells in the body
March 19, 2019 - Heart attack patients who are taken to heart care centres directly survive longer
March 19, 2019 - IVF babies have increased in birthweight over the past 25 years, study reveals
March 19, 2019 - Study highlights the need for psychiatric care to be integrated into cancer treatment
March 19, 2019 - Testosterone treatment lowers recurrence rates in low-risk prostate cancer patients
March 19, 2019 - Caterpillars could hold the secret to new treatment for Osteoarthritis
March 19, 2019 - Parkinson’s treatment delivers a power-up to brain cell ‘batteries’
March 19, 2019 - Stanford launches new Institute for Human-Centered Artificial Intelligence
March 19, 2019 - Wireless earphones may cause cancer
March 18, 2019 - ACC/AHA guideline for prevention of cardiovascular disease released
March 18, 2019 - UTA nursing professor receives $6.575 million to attack musculoskeletal diseases
March 18, 2019 - Gene medication shows promise to treat spinal cord injuries
March 18, 2019 - First Human Study of “Robotic” RaniPill™ Capsule to Replace Injections Announced by Rani Therapeutics
March 18, 2019 - Food Allergy Testing: MedlinePlus Lab Test Information
March 18, 2019 - Altered brain activity patterns of Parkinson’s captured in mice
March 18, 2019 - Apple Heart Study demonstrates ability of wearable technology to detect atrial fibrillation | News Center
March 18, 2019 - Cardiovascular benefits of diabetes drug extend across a wide spectrum of patients, shows study
March 18, 2019 - Novel cardiac pump shows superior outcomes in patients with advanced heart failure
March 18, 2019 - U.S. FDA Grants Priority Review for Fedratinib New Drug Application in Myelofibrosis
March 18, 2019 - Living like a caveman won’t make you thin—but it might make you healthy
March 18, 2019 - Modified immune cells issue alert when detecting cancer in mice | News Center
March 18, 2019 - Dementia caregivers design robots for alleviating stress and increasing joyful moments
March 18, 2019 - VR technology could help improve balance in humans
March 18, 2019 - Study demonstrates effective way to slow progression of cerebrovascular disease in older adults
March 18, 2019 - Premature babies also have protective anti-viral antibodies
March 18, 2019 - Painkillers taken by pregnant mothers unlikely to cause asthma in the child
March 18, 2019 - Fibromyalgia can be reliably detected in blood samples
March 18, 2019 - Marijuana use has dropped among most teens after legalization
March 18, 2019 - Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25mg, 50mg, And 100mg Due to The Detection of Trace Amounts Of N-Nitroso N-Methyl 4-Amino Butyric Acid (NMBA) Impurity Found in The Active Pharmaceutical Ingredient (API)
March 18, 2019 - Researchers identify early home and family factors that contribute to obesity
March 18, 2019 - Fate and festivity: Match Day 2019
March 18, 2019 - Study finds TAVR to be as good as open-heart surgery for patients at low surgical risk
March 18, 2019 - EU-funded project is developing new tools for diagnosing cancer
March 18, 2019 - Gluten, lactose, food dyes in pills could be causing side effects finds study
March 18, 2019 - Taking painkillers during pregnancy is not responsible for asthma risk in children, study shows
March 18, 2019 - Prediagnosis Psychiatric Care Linked to Worse Cancer Mortality
March 18, 2019 - Paris hospital halts stool study after donor deluge
March 18, 2019 - Partial oral antibiotic therapy shows efficacy and safety in patients with infectious endocarditis
March 18, 2019 - Olympus improves access to science education through BioBus collaboration
March 18, 2019 - Depression screening does not improve quality of life in heart attack patients
March 18, 2019 - Echocardiography may aid in patient selection for TMVR
March 18, 2019 - Are ‘Inactive’ Ingredients in Your Drugs Really So Harmless?
March 18, 2019 - Wearable technology can safely identify atrial fibrillation
March 18, 2019 - Scientists tackle rare retinal disease in unique research project
March 18, 2019 - Death By A Thousand Clicks
March 18, 2019 - Absorbable, antibiotic-eluting envelope can reduce rate of cardiac device infections
March 18, 2019 - Hormonal treatment associated with depression in men with prostate cancer
March 18, 2019 - Porvair Sciences launches reinforced 96-well deep round microplate
March 18, 2019 - Simplified catheter ablation could slash waiting lists for atrial fibrillation patients
March 18, 2019 - BFR therapy as part of rehabilitation following ACL surgery may slow bone loss
March 18, 2019 - A human model to test implants for cataract surgery
March 18, 2019 - New risk adjustment model could reduce financial penalty for safety net hospitals
March 18, 2019 - NHS cancer patients’ wait to start treatment worrying
March 18, 2019 - Inventiva Announces Results from Phase IIb Clinical Trial with Lanifibranor in Systemic Sclerosis
March 18, 2019 - Cologuard
March 18, 2019 - Researchers find evidence of prenatal environment tuning genomic imprinting
March 18, 2019 - Dolomite Bio launches novel Nadia product family for single-cell research
March 18, 2019 - Intellipharmaceutics Announces Resubmission of New Drug Application to the U.S. FDA for its Oxycodone ER
March 18, 2019 - Excessive gestational weight gain tied to maternal morbidity
March 18, 2019 - RCEM issues position statement on metrics to supplement four-hour standard target
March 17, 2019 - Noncontrast Brain MRI Effective for Monitoring Multiple Sclerosis
March 17, 2019 - Brain region plays key role in regulation of parenting behavior, study finds
March 17, 2019 - Natural speed limit on DNA replication sets pace for life’s first steps
March 17, 2019 - New research reveals overlooked impact of herbicide glyphosate on the environment
March 17, 2019 - Molecular patterns could help predict relapse risk in breast cancer patients
March 17, 2019 - Study confirms sensitivity of microbiological cultures for detecting cholera
March 17, 2019 - Scientists Spot Clues to Predicting Breast Cancer’s Return
March 17, 2019 - Scientists identify gene that keeps PTSD-like behavior at bay in female mice
March 17, 2019 - New method would allow doctors to detect earliest stages of cancers in the lymph nodes
March 17, 2019 - Cholesterol protein discovery raises hope for smarter drugs
March 17, 2019 - New insect medium delivers high viable cell density growth and protein yield
Scientists identify more aggressive chemotherapy treatment for childhood brain cancer

Scientists identify more aggressive chemotherapy treatment for childhood brain cancer

image_pdfDownload PDFimage_print

Scientists led by Newcastle University have been able to identify the group of children needing more intensive, aggressive chemotherapy treatment for the most common form of brain cancer.

The chromosome signature they have identified in medulloblastoma could allow medics to adapt treatment so that each child is targeted individually, improving the 60% survival rate for high-risk patients.

The study’s findings, published today in The Lancet Oncology, also shows that many youngsters with medulloblastoma could avoid unnecessary doses of chemotherapy and radiotherapy with less toxic side effects.

While others, who have the most serious form of the disease, may be targeted with more intensive chemotherapy. Currently all patients receive the same treatment.

Personalised treatment

Professor Steve Clifford, Director of the Northern Institute for Cancer Research, Newcastle University, UK, led the European study with Dr Edward Schwalbe, from Northumbria University.

Professor Clifford said: “Our findings provide a new blueprint for the personalisation of treatment in medulloblastoma so that all children are not given the same intensity of therapy.

“This study shows that low-risk patients may receive kinder treatments aimed at reducing toxicity and side effects, while targeting more intensive treatments to the high-risk patients who need it most.

“Medulloblastoma is the most common malignant childhood brain tumour and it is important that we have improved outcomes for patients with this disease.

“Through a greater understanding of brain tumours we hope to increase the cure rate but critically, for those children who survive, we want to make sure their quality of life is good after treatment.”

Scientists at Newcastle University’s Wolfson Childhood Cancer Research Centre worked with Northumbria University and European collaborators to examine the molecular pathology of the cancer.

The study is part of the largest completed clinical trial of medulloblastoma undertaken across Europe and it is hoped that it will lead to significantly improved outcomes for patients in the future.

Clinical groups

Experts identified that children with the cancer can be split into two clinical groups – about half of which are low-risk with close to 100% survival, while the other half are high-risk, with 60% survival.

The study analysed data from the PNET4 clinical trial of standard-risk medulloblastoma, which ran from 2001-2006, and was partly funded by Cancer Research UK.

The standard-risk patients involved in the cohort were children with no recognised risk factors for the disease and who would be expected to have a survival rate of around 80% after five years.

Working with the University of Bonn in Germany, the Newcastle and Northumbria team identified recurrent patterns of chromosome gains and losses in medulloblastoma tumours.

The team found a chromosome signature that identifies a group of patients with 100% survival rates, and a high-risk group with just 60% survival.

Dr Ed Schwalbe, Senior Lecturer in Bioinformatics and Biostatistics at Northumbria University, said: “In this study, we identified an easily testable chromosome signature that predicts excellent outcomes for children with medulloblastoma. Importantly, we also show that this signature works as expected in an independent set of patients.

“Looking forward, we hope that children whose tumours have this signature could be treated less aggressively, reducing the life-long side effects of the gruelling treatments, while maintaining a cure.”

Medulloblastoma is the most common high grade childhood tumour, accounting for 15%-20% of all childhood brain tumours.

Current treatment for the cancer is surgery to remove the tumour, followed by radiotherapy and an intensive course of chemotherapy.

Researchers are now working with the European trial group to implement the findings of this study clinically as part of forthcoming trials to adapt therapy in the future.

Case study

Schoolboy Olly McKenna was diagnosed with medulloblastoma less than a year ago and has battled back to health.

The 12-year-old, from Bill Quay, Gateshead, had surgery for nine hours to remove his aggressive tumour and underwent months of gruelling radiotherapy and chemotherapy.

Today his parents Jason and Jill have welcomed the research being undertaken in the North East into this form of brain cancer.

Jill, 44, a superintendent radiographer, said: “It is incredibly important that as much research as possible is done into medulloblastoma so that patients receive the best treatment options.

“Each child currently diagnosed with the condition is given the same treatment and this level of toxicity makes the youngsters very ill – for parents it’s awful watching their child go through that.

“To know that research has identified that therapy should be tailored to each individual child is fantastic as it will mean that children will not be given toxic treatment unnecessarily.

“The most important thing is that children have as few side effects as possible so that they can continue to have a good quality of life during and after treatment.”

Source:

https://www.ncl.ac.uk/press/articles/latest/2018/11/medulloblastomaresearch/

Tagged with:

About author

Related Articles